76322-41-3Relevant articles and documents
Piperazinyl CCR1 antagonists-optimization of human liver microsome stability
Brown, Matthew F.,Bahnck, Kevin B.,Blumberg, Laura C.,Brissette, William H.,Burrell, Sara A.,Driscoll, James P.,Fedeles, Flavia,Fisher, Michael B.,Foti, Robert S.,Gladue, Ronald P.,Guzman-Martinez, Aikomari,Hayward, Matthew M.,Lira, Paul D.,Lillie, Brett M.,Lu, Yi,Lundquist, Greg D.,McElroy, Eric B.,McGlynn, Molly A.,Paradis, Timothy J.,Poss, Christopher S.,Roache, James H.,Shavnya, Andrei,Shepard, Richard M.,Trevena, Kristen A.,Tylaska, Laurie A.
, p. 3109 - 3112 (2008/03/13)
The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described.
Methods of using piperazine derivatives
-
, (2008/06/13)
The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
Novel sulfonic acid derivatives
-
, (2008/06/13)
A compound of the formula or the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R1, R2, R3 and R5 are as defined above useful to treat inflammation and other immune disorders.
